Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

NCT02381080 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Chronic Lymphocytic Leukemia

Interventions

DRUG: Ibrutinib
DRUG: Erythromycin
DRUG: Voriconazole

Sponsor

Janssen Research & Development, LLC